Bias analysis to guide new data collection

International Journal of Biostatistics

Volumn 8, Issue 2, 2012, Pages

  Lash, Timothy L ^a   Ahern, Thomas P ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bias analysis; Causal inference; Epidemiologic methods

Indexed keywords

CYTOCHROME P450 2D6; DICOUMAROL; PHENPROCOUMON; TAMOXIFEN;

ARTICLE; BIAS ANALYSIS; BREAST CANCER; CANCER RESISTANCE; CANCER RISK; DATA ANALYSIS; DECISION MAKING; DNA POLYMORPHISM; GENE FUNCTION; GENOTYPE; HEART VALVE REPLACEMENT; HUMAN; HYPOTHESIS; INFORMATION PROCESSING; QUANTITATIVE ANALYSIS; STATISTICAL PARAMETERS; STROKE; SYSTEMATIC ERROR; UROGENITAL TRACT CANCER;

ANTICOAGULANTS; BIAS (EPIDEMIOLOGY); BIOSTATISTICS; BREAST NEOPLASMS; CAUSALITY; CYTOCHROME P-450 CYP2D6; DATA COLLECTION; DRUG RESISTANCE, NEOPLASM; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; NEOPLASMS; POLYMORPHISM, GENETIC; TAMOXIFEN; VITAMIN K;

EID: 84857735356     PISSN: None     EISSN: 15574679     Source Type: Journal    
DOI: 10.2202/1557-4679.1345     Document Type: Article

References (43)

1. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717.
2. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg D, Earl HM, Dunning AM, Pharoah PD, Caldas C (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12(4):R64.
3. Ahern TP, Pedersen L, Svaerke C, Rothman KJ, Sorensen HT, Lash TL (2011) The association between vitamin K antagonist therapy and site-specific cancer incidence, estimated by using heart valve replacement as an instrumental variable. Am J Epidemiol In Press.
4. Aurigemma GP, Gaasch WH (2010) Antithrombotic therapy in patients with prosthetic heart valves. In UpToDate, Otto CM (ed) UpToDate: Waltham, MA
5. Blichert-Toft M, Christiansen P, Mouridsen HT (2008) Danish Breast Cancer Cooperative Group-DBCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 47(4):497-505. (Pubitemid 351878432)
6. Blumentals WA, Foulis PR, Schwartz SW, Mason TJ (2004) Does warfarin therapy influence the risk of bladder cancer? Thromb Haemost 91(4):801-805. (Pubitemid 38477462)
7. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S (2006a) Evaluating shortterm drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 17(3):268-275.
8. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S (2006b) Instrumental variable analysis of secondary pharmacoepidemiologic data. Epidemiology 17(4):373-374. (Pubitemid 44305509)
9. Bross I (1954) Misclassification in 2×2 tables. Biometrics 478-489.
10. Bross ID (1967) Pertinency of an extraneous variable. J Chronic Dis 20(7):487-495.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (5).
12. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nussler A, Neuhaus P, Zanger UM, Eichelbaum M, Murdter TE (2002) The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54(2):157-167. (Pubitemid 35024939)
13. Cronin-Fenton DP, Lash TL (2011) Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol 4(3):363-377.
14. Desta Z, Flockhart DA (2007) Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol 25(33):5147-5149. (Pubitemid 350232242)
15. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310(3):1062-1075. (Pubitemid 39108928)
16. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19(1):56-61.
17. Goodman LS, Gilman A. (2006) Goodman & Gilman's the Pharmacological Basis of Therapeutics. McGraw-Hill: New York
18. Greenland S, Lash TL (2008) Bias Analysis. In Modern Epidemiology, Rothman KJ, Greenland S, Lash TL (eds) pp 345-380. Lippincott Williams & Wilkins: Philadelphia
19. Greenland S (1996) Basic methods for sensitivity analysis of biases. Int J Epidemiol 25(6):1107-1116. (Pubitemid 27013514)
20. Greenland S (2000) An introduction to instrumental variables for epidemiologists. Int J Epidemiol 29(4):722-729. (Pubitemid 30612241)
21. Greenland S, Pearl J, Robins JM (1999) Causal diagrams for epidemiologic research. Epidemiology 10 (1).
22. Hernan MA, Robins JM (2006) Instruments for causal inference: an epidemiologist's dream? Epidemiology 17(4):360-372. (Pubitemid 44305508)
23. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1):30-39.
24. Jordan VC (2007) New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72(13):829-842. (Pubitemid 47410069)
25. Katzung BG (2004) Basic & Clinical Pharmacology. Lange Medical Books/McGraw Hill: New York
26. Lash TL (2007) Heuristic thinking and inference from observational epidemiology. Epidemiology 18(1):67-72. (Pubitemid 46005911)
27. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sorensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S (2011) CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark. J Natl Cancer Inst 103(6):489-500.
28. Lash TL, Fox MP, Fink AK (2009a) Applying Quantitative Bias Analysis to Epidemiologic Data. Springer: New York
29. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S (2009b) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10(8):825-833.
30. Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55(5):471-478. (Pubitemid 40568978)
31. Myrand S, Sekiguchi K, Man M, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, Eddy S, Dostalik J, Mount J, Azuma J, Fujio Y, Jang IJ, Shin SG, Bleavins M, Williams J, Paulauskis J, Wilner K (2008) Pharmacokinetics/ Genotype Associations for Major Cytochrome P450 Enzymes in Native and First-and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations. Clin Pharmacol Ther 84(3):347-361.
32. Pengo V, Denas G, Jose SP, Pengo MF (2010) Cancer prevention and vitamin K antagonists: an overview. Thromb Res 125 Suppl 2 S103-S105.
33. Pengo V, Noventa F, Denas G, Pengo MF, Gallo U, Grion AM, Iliceto S, Prandoni P (2011) Long-term use of vitamin K antagonists and incidence of cancer: A population-based study. Blood 117(5):1707-1709.
34. Prandoni P, Piccioli A (2006) Thrombosis as a harbinger of cancer. Curr Opin Hematol 13(5):362-365. (Pubitemid 44168458)
35. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH (2007) Pathways to tamoxifen resistance. Cancer Lett 256(1):1-24. (Pubitemid 47333324)
36. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60(2):284-295. (Pubitemid 27058401)
37. Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, Schwab M, Brauch H (2010) CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 16(17):4468-4477.
38. Schulman S, Lindmarker P (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 342(26):1953-1958. (Pubitemid 30419090)
39. Seruga B, Amir E (2010) Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 122(3):609-617.
40. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95(23):1758-1764. (Pubitemid 38008898)
41. Tagalakis V, Tamim H, Blostein M, Collet JP, Hanley JA, Kahn SR (2007) Use of warfarin and risk of urogenital cancer: a population-based, nested casecontrol study. Lancet Oncol 8(5):395-402. (Pubitemid 46621759)
42. Taliani MR, Agnelli G, Prandoni P, Becattini C, Moia M, Bazzan M, Ageno W, Tomasi C, Guazzaloca G, Ambrosio GB, Bertoldi A, Salvi R, Poggio R, Silingardi M (2003) Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 1(8):1730-1733.
43. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279-287.